Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Stomach Neoplasms × folfirinox × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 17 Neoplasms 4 Urachal cancer 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Pancreatic Cancer Metastatic 1 Neoplasm Metastasis 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Hepatocellular 1 Borderline Resectable Pancreatic Cancer 1 Biliary Tract Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 144 Capecitabine 95 Fluorouracil 89 Docetaxel 73 Cisplatin 72 S 1 (combination) 68 Leucovorin 63 Paclitaxel 50 Irinotecan 49 pembrolizumab 30 apatinib 28 Trastuzumab 27 sintilimab 25 Bevacizumab 20 Surgical Procedures, Operative 18 Radiotherapy 18 titanium silicide 13 camrelizumab 13 Ramucirumab 13 tislelizumab 12 Nivolumab 12 Hyperthermic Intraperitoneal Chemotherapy 12 Folfox protocol 12 Epirubicin 12 Drug Therapy 12 Cetuximab 12 Tegafur 10 XELOX 9 HMPL-013 9 Carboplatin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03825861 2020-11-10

FOLFIRINOX

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡